Jula Inrig, EVP, Head of R&D & CMO at Travere Therapeutics, Inc. (TVTX), sold 44,674 shares at $62.02 ($2.8M) on 2026-09-15, disclosed to the SEC on 2026-09-17.
Scheduled sale ($2.8M) by EVP, Head of R&D & CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.02 | 25,390 | $1.6M | 56.5% |
| 2 | $62.62 | 17,284 | $1.1M | 38.9% |
| 3 | $63.69 | 1,600 | $102K | 3.7% |
| 4 | $65.31 | 400 | $26K | 0.9% |
| Total | $62.34 avg | 44,674 | $2.8M | 100% |
| Filing → |
| TVTX | SELL | 2026-02-05 | $57K | — | Filing → |
| TVTX | SELL | 2026-02-03 | $223K | — | Filing → |
| TVTX | SELL | 2026-01-07 | $98K | — | Filing → |